Chronic myelogenous leukemia

COVID-19 in persons with chronic myeloid leukaemia

Weiming Li¹ · Danyu Wang² · Jingming Guo³ · Guolin Yuan⁴ · Zhuangzh Yang⁵ · Robert Peter Gale⁶ · Yong You¹ · Zhichao Chen¹ · Shiming Chen⁷ · Chucheng Wan⁸ · Xiaojian Zhu⁹ · Wei Chang¹⁰ · Lingshuang Sheng⁹ · Hui Cheng¹¹ · Youshan Zhang¹² · Qing Li¹¹ · Jun Qin¹³ · Hubei Anti-Cancer Association · Li Meng⁹ · Qian Jiang¹⁴

Received: 12 April 2020 / Revised: 23 April 2020 / Accepted: 27 April 2020 / Published online: 18 May 2020
© The Author(s), under exclusive licence to Springer Nature Limited 2020

Abstract
We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased SARS-CoV-2 infection surveillance and possible protective isolation.

Introduction
Some data suggest persons with cancer are more susceptible to SARS-CoV-2-infection and to develop coronavirus disease 2019 (COVID-19) compared with normals (1% [95% Confidence Interval (CI), 0.6, 1.7%] versus 0.1% [0, 0.12%]), but these estimates are controversial and it is unclear if this increased risk applies to persons with all cancer types [1–8].

These authors contributed equally: Weiming Li, Danyu Wang, Jingming Guo, Guolin Yuan, Zhuangzh Yang

Members of the Hubei Anti-Cancer Association are listed below.

Supplementary information The online version of this article (https://doi.org/10.1038/s41375-020-0853-6) contains supplementary material, which is available to authorized users.

Weiming Li
lee937@126.com
Li Meng
mengli@tjh.tjmu.edu.cn
Qian Jiang
jiangqian@medmail.com.cn

Extended author information available on the last page of the article

One study of 125 hospitalised persons with haematological cancers had a 10 percent (6, 17%) case rate of COVID-19 but none of their subjects had chronic myeloid leukaemia (CML) [9]. We performed a cross-sectional survey of non-hospitalized persons with CML receiving tyrosine kinase-inhibitor (TKI)-therapy in Hubei Province to explore the prevalence and clinical features of COVID-19 during the SARS-CoV-2 pandemic. Prevalence of COVID-19 in persons with CML, 0.9 percent (0.1, 1.8%) was substantially higher than normals but lower than hospitalised persons with haematological cancers. Clinical features of COVID-19 in our subjects and otherwise normal persons were similar. We identified co-variates associated with an increased risk of developing COVID-19. Persons with these co-variates may benefit from increased SARS-CoV-2-infection surveillance and possible protective isolation.

Methods

Survey design

From February 15, 2020 to April 10, 2020 persons with CML receiving TKI-therapy from Hubei Province were
recruited from 29 centres of the Hubei Anti-Cancer Association. An online questionnaire was distributed and collected by physicians at each centre. Persons with CML or their family (if they were too sick or died) were asked to complete the questionnaire which included two dimensions (Supplementary 1). The 1st included 16 questions assessing demographics, co-morbidities, CML-related data including diagnosis, therapy and response. The 2nd included 12 questions related to COVID-19 including exposure history, symptoms of acute respiratory illness such as fever, cough, shortness of breath and fatigue, diagnosis, treatment and outcome. Missing or unclear data items were collected and clarified by direct communication between physicians and the patient, their family and/or health-care providers. The study was approved by the Ethics Committee of Union Hospital, Tongji Medical College who waived the requirement for written informed consent. Data were analyzed as of April 11, 2020.

Diagnosis, monitoring and response to TKI-therapy of CML

Diagnosis, disease phase, monitoring and response to TKI-therapy were based on European LeukemiaNet recommendations [10].

Diagnosis, severity and outcome of COVID-19

Infection was confirmed by qualitative real time polymerase chain reaction (qRT-PCR) for SARS-CoV-2. COVID-19 was diagnosed according to the World Health Organisation criteria (https://apps.who.int/iris/bitstream/handle/10665/331506/WHO-2019-nCoV-SurveillanceGuidance-2020.6-eng.pdf). Severity of COVID-19 was graded as follows (http://www.nhc.gov.cn/zyyjy/s7653p/202002/3b09b894a9b4204a79db5b8912d4440.shtml): (1) mild—mild clinical symptoms, no pneumonia on lung CT scan; (2) common—cough and lung CT with pneumonia; (3) severe—respiratory distress (respiratory rate > 30/min, oxygen saturation (O₂Sat) ≤ 93% at rest and/or ratio of arterial oxygen partial pressure to fractional inspired oxygen ≤ 300 mmHg (P_{aO2}/FiO₂); and (4) critical—criteria of respiratory failure and mechanical ventilation, shock, organ failure (other than lung) and/or intensive care unit hospitalisation. Therapy of COVID-19 was according to the Novel Coronavirus Pneumonia Prevention and Control Programme of the National Health Commission of China (http://www.nhc.gov.cn/zyyjy/s7653p/202002/3b09b894a9b4204a79db5b8912d4440.shtml).

Outcomes other than death were defined as follows: (1) cure—two successive negative RT-PCR tests > 24 h apart and asymptomatic; (2) improved—improvement in signs, symptoms, and laboratory parameters and no progression on lung CT scan; (3) progressing—increase in symptoms and/or progression of lung CT scan findings; (4) stable—not progressing or improving (http://www.nhc.gov.cn/zyyjy/s7653p/202002/3b09b894a9b4204a79db5b8912d4440.shtml).

Statistical analysis

Descriptive analysis results are presented as median (range) or number (percentage) as appropriate. Pearson Chi-square or Fisher’s exact test for categorical variables and Mann–Whitney U/Kruskal–Wallis tests (for continuous variables) were used to measure between-group differences. Variables with P < 0.05 were considered significant. Analyses were conducted with SPSS version 22.0 software (SPSS Inc., Chicago, IL, USA).

Results

Subject variables

Among 551 persons with CML receiving TKI-therapy in the Hubei Anti-Cancer Association, 476 filled out electronic questionnaires. Another 75 were completed telephonically by health-care providers. Questionnaires from 21 subjects not resident in Hubei Province during the outbreak were excluded. Data from 530 subjects were included in this report. Two hundred and ninety-six (56%) were male. Median age was 44 years (range, 6–89 years). Ninety-five (18%) were ≥60 years. One hundred and forty (26%) had ≥1 co-morbidity(ies). Five hundred and nineteen (98%) were in the chronic phase (CP) at diagnosis of CML. One subject was synchronously diagnosed with CML by RT-PCR and COVID-19. 346 (65%) were receiving imatinib when they answered the questionnaire, 102 (19%), dasatinib; 59 (11%), nilotinib; 18, HQP1351 (a 3rd generation TKI under study in a clinical trial); 3, ponatinib; and 2, flutatinib (a new 2nd generation TKI developed in China). Median TKI-therapy duration was 42 months (range, 1–182 months). All 530 were in the CP when they answered the questionnaire. Eighty-one (15%) had a complete haematologic response (CHR); 52 (10%), a complete cytogenetic response (CCyR); and 387 (73%), a major molecular response (MMR).

All 530 subjects continued resident in Hubei Province during the epidemic. Four reported close contact with SARS-CoV-2 infected persons. Eighteen subjects had an acute respiratory illness including fever (n = 8), cough (n = 7), sore throat (n = 4), fatigue (n = 3), and shortness of breath (n = 2). Eleven had mild symptoms, were isolated at home and recovered within 2–4 days. Seven others had moderate or severe illness and were hospitalised. Two subjects with a negative qRT-PCR for SARS-CoV-19 and...
no abnormality of lung CT scan were excluded. Four subjects had confirmed COVID-19. One subject was classified as probable COVID-19 because of no qRT-PCR SARS-CoV-2 testing. Cumulative prevalence of confirmed and probable COVID-19 cases was 0.9 percent (0.1, 1.8%).

Comparison of baseline co-variates of the subjects with and without COVID-19

Baseline co-variates of subjects with \( n = 5 \) and without COVID-19 \( n = 525 \) are shown in Table 1. Subjects with COVID-19 were more likely to have been in the accelerated or blast phase at diagnosis (2 of 5 versus 2%; \( P = 0.004 \)), no CHR at diagnosis of COVID-19 (2 of 5 versus 2%; \( P = 0.003 \)), have ≥1 co-morbidity(ies) (4 of 5 versus 26%; \( P = 0.024 \)) and have contact with confirmed or suspected persons (1 of 5 versus 0.6%, \( P = 0.037 \)). 1 of 21 (5%) subjects receiving 3rd generation TKI developed COVID-19 versus 3 of 346 (1%) subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs, \( P = 0.095 \).

There was no difference between the cohorts in sex, age and TKI-therapy duration.

Clinical features and outcomes of the subjects with COVID-19

Clinical features and outcomes of the five subjects with confirmed or probable COVID-19 are summarised in Table 2 and Supplementary 2. Four subjects with confirmed mild (N = 1) or common (n = 3) COVID-19 had typical symptoms and/or lung CT scan findings; all recovered. An older female subject (case 5) with probable critical severe COVID-19 had typical lung CT scan findings (Fig. 1) and developed ARDS. Her condition deteriorated rapidly and she died of multiple organ failure. Four subjects remained on TKI-therapy during COVID-19 treatment.

Discussion

Whether persons with CML are immune compromised is controversial [11]. However, TKI-therapy is immune suppressive [12–14]. Based on these data one might expect a higher incidence and prevalence of SARS-CoV-2-infection and higher case- and case-fatality rates of COVID-19 in persons with CML compared with normals. We found a 0.9 percent prevalence of COVID-19 in persons with CML receiving TKI-therapy in Hubei Provence, ninefold higher than the reported 0.1 percent (0.11, 0.12%) incidence by April 10, 2020 in the general population (http://en.nhc.gov.cn/2020-04/11/c_79032.htm). Clinical features of the confirmed COVID-19 in our survey were like that reported in Hubei Province [15–17]. One subject died but our sample size is too small to compare with the published case-fatality rate of about 4% [18, 19].

We found several co-variates associated with an increased risk to develop COVID-19. Including exposure to someone infected with SARS-CoV-2, no CHR and co-morbidity(ies). There was also an increased risk of

| Table 1 Subject co-variates at diagnosis of CML and onset of COVID-19. |
|-----------------|-----------------|-----------------|
| Variable        | COVID-19 \( n = 5 \) | No-COVID-19 \( n = 525 \) | \( P \) value |
| Male, \( n \)   | 3               | 293             | 0.659 |
| Age at onset of COVID-19, y, median (range) | 47 (41–89) | 44 (6–80) | 0.951 |
| Disease phase at diagnosis of CML, \( n \) | | | 0.004 |
| CP              | 3               | 516             | | |
| AP or BP\(^a\) | 2               | 9               | | |
| Current TKI used at onset of COVID-19\(^b\), \( n \) | | | 0.096 |
| Imatinib        | 3               | 343             | | |
| 2nd generation TKI | 0            | 162             | | |
| 3rd generation TKI\(^c\) | 1            | 20              | | |
| Current TKI-therapy line at onset of COVID-19\(^b\), \( n \) | | | 0.197 |
| 1st line        | 3               | 402             | | |
| 2nd line        | 0               | 99              | | |
| 3rd line        | 1               | 24              | | |
| TKI-therapy duration by onset of COVID-19, mo, median (range) | 27 (0–133) | 42 (2–188) | 0.811 |
| Response at onset of COVID-19, \( n \) | | | 0.003 |
| No CHR          | 2               | 8               | | |
| CHR             | 0               | 81              | | |
| CCyR            | 1               | 51              | | |
| MMR             | 2               | 385             | | |
| Co-morbidity, \( n \) | 4             | 136             | 0.024 |
| Cardio- and cerebro-vascular disease | 3 | 47 | |
| Diabetes        | 1               | 15              | | |
| Other           | 0               | 74              | | |
| Contact with suspected or confirmed persons | 1 | 3 | 0.037 |

\(^a\) One subject in those with no-COVID-19 was in the blast phase at diagnosis of CML.

\(^b\) One person did not start TKI-therapy at onset of COVID-19.

\(^c\) 3rd generation TKIs included ponatinib and HQP1351.

\(AP\) accelerated phase, \(BP\) blast phase, \(CCyR\) complete cytogenetic response, \(CHR\) complete haematologic response, \(CML\) chronic myeloid leukaemia, \(CP\) chronic phase, \(COVID-19\) coronavirus disease 2019, \(MMR\) major molecular response, \(mo\) month(s), \(TKI\) tyrosine kinase-inhibitor, \(y\) years.
developing COVID-19 in subjects in advanced phase CML at diagnosis even when they achieved a CCyR or MMR at the time of the pandemic. One of 21 subjects receiving 3rd generation TKIs developed COVID-19 compared with 3 of 346 subjects receiving imatinib and none of 162 subjects receiving 2nd generation TKIs ($P = 0.096$). These data suggest possibly different risks but need confirmation.

There are no data whether 3rd generation TKI is more immune suppressive than other TKIs. Also, 1 of 2 subjects receiving flumatinib developed COVID-19. However, one subject had synchronous diagnoses of CML and COVID-19 excluding a causative. Why subjects with advanced leukemia at diagnosis had a higher risk of COVID-19 despite responding well to TKI-therapy is unclear.

There are several limitations to our study. First, there were selection biases. Because the survey was made available online, respondents were self-selected. These persons had computer access and competence and tended to be proactive in seeking information and resources for their care. As such, the likelihood of detecting SARS-CoV-2-infection and COVID-19 is higher than in the general Hubei population. Second, not all 18 subjects with acute respiratory illness were tested for SARS-CoV-19-infection so our prevalence estimate may be an under-estimate. However,
COVID-19 in persons with chronic myeloid leukaemia

Xiaogan, China; 19Gezhouba Central Hospital, Yichang, China; 17Hubei Anti-Cancer Association.

According to Chinese government policy, people with mild illness were isolated at home and not tested for SARS-CoV-2-infection. Eleven of these 18 had no lung CT scan we may have underestimated the prevalence of COVID-19 in our sample.

In summary, our survey suggests that although persons with CML receiving TKI-therapy developing COVID-19 may be higher than the general population the absolute case-rate is very low and clinical features are like normals. Persons with no CHR, with co-morbidity(ies), with advanced phase at diagnosis despite responding to TKI-therapy and those exposed to someone with SARS-CoV-2-infection may benefit from increased surveillance and possible protective isolation.

Acknowledgements We thank patients, families and physicians from Hubei Anti-Cancer Association (XLZ, DZJ, HXW, JH, YFZ, BC, QW, ZPH, QHL, YB, DLZ, XHZ, ZZ, RYG, JD, YPW, HBR, HH, YHW, and HX) who participated in the study. This study is funded by the Natural Science Foundation of China (Nos. 81873440, 81770161, 81770162, 81770163, 81670164, 81770161, 81770043, and 81770162). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.

Hubei Anti-Cancer Association Yicheng Zhang9, Weiming Li1, Yang Chao2, Jingming Guo3, Guolin Yuan4, Zhanzhai Yang5, Shiming Chen6, Chuancheng Wan7, Wei Chang8, Hui Cheng9, Youshan Zhang10, Jun Qiu11, Xuean Zuo12, Dazuo Jiang13, Hongxiong Wang14, Jun Huang15, Youfang Zhao16, Bin Chen17, Qiu Gu18, Zhiping Huang19, Qihuai Liu20, Ying Bao21, Dalin Zhang22, Xinhuai Zhang23, Zhe Zhao24, Renying Ge25, Jie Du26, Hongbo Ren27, Hong Han28, Yunhui Wei29, Hang Xiang30.

Affiliations Hubei Provincial Hospital of TCM, Wuhan, China; 21The Fifth Hospital of Wuhan, Wuhan, China; 22Jingzhou Central Hospital, Jingzhou, China; 23Affiliated Dongfeng Hospital, Hubei University of Medicine, Shiyan, China; 24Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, China; 25Tianmen First People’s Hospital, Tianmen, China; 26The General Hospital of Central Theater Command, Wuhan, China; 27Minda Hospital, Hubei Minzu University, Enshi, China; 28Xinning Center Hospital, Xinning, China; 29Xiantao First People’s Hospital, Xiantao, China; 30Liuyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 31Changzhou Hospital, Xiangyang, China; 32Enshi Central Hospital, Enshi, China.

Author contributions WML, QJ, LM designed the study. DYW, JMG, GLY, ZZY, YY, ZCC, SMC, CCW, XJZ, WC, LSS, HC, YSZ, QL, and JQ, collected the data. WML, QJ and RPG analyzed the data and help prepare the typescript. All authors approved final approval and supported submission for publication.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.

2. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;S0923-7534(20)36383-3.

3. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e180.

4. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e181.

5. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2020.0980.

6. Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A war on two fronts: cancer care in the time of COVID-19. Ann Intern Med. 2020. https://doi.org/10.7326/M20-1133.

7. The Lancet Oncology. COVID-19: global consequences for oncology. Lancet Oncol. 2020;21:467.

8. Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagnio F, EHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020. In press.

9. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020. In press.

10. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

11. Gale RP, Opelz G. Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. Leuk Res. 2017;57:109–11.
12. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484–91.

13. Thiant S, Moutuou MM, Laborde P, Sidi Boumedine R, Leboeuf DM, Busque L, et al. Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. Blood Cancer J. 2017;7:e551.

14. Dörfel D, Lechner CJ, Joas S, Funk T, Gutknecht M, Salih J, et al. The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells. Cancer Immunol Immunother. 2018;67:775–83.

15. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032.

16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.

17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

18. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.

19. Spychalski P, Blażyńska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020:S1473-3099(20)30246-2.

Affiliations

Weiming Li1 · Danyu Wang2 · Jingming Guo3 · Guolin Yuan4 · Zhuangzhi Yang5 · Robert Peter Gale6 · Yong You1 · Zhichao Chen1 · Shiming Chen7 · Chucheng Wan8 · Xiaoqian Zhu9 · Wei Chang10 · Lingshuang Sheng11 · Hui Cheng11 · Youshan Zhang12 · Qing Li11 · Jun Qin13 · Hubei Anti-Cancer Association · Li Meng9 · Qian Jiang14

1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong Medical University, Shenzhen, Guangdong, China
3 Yi Chang Central People’s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China
4 Xiangyang Central Hospital, The Affiliated Hospital of Huai University of Arts and Science, Xiangyang, Hubei, China
5 Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei, China
6 Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK
7 Huangshi Central Hospital, Huangshi, Hubei, China
8 Affiliated Taihe Hospital of Hubei University of Medicine, Shiyuan, Hubei, China
9 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
10 China Resources & Wisco general hospital, Wuhan, Hubei, China
11 Wuhan No.1 Hospital, Wuhan, Hubei, China
12 Jingzhou First People’s Hospital, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China
13 Renmin Hospital, Hubei University of Medicine, Shiyuan, Hubei, China
14 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China